Adcentrx Therapeutics Announces FDA Clearance of Investigational New Drug Application for ADRX-0706, a Novel ADC Targeting Nectin-4 for the Treatment of Advanced Solid TumorsJuly 17, 2023
Adcentrx Therapeutics Announces Completion of $38 million Series A+ Financing Led by Eight Roads VenturesApril 24, 2023
Adcentrx and AvantGen Enter a New Partnership with a Three-year, Multi-target Collaboration to Discover Antibodies for Novel Antibody-drug ConjugatesFebruary 14, 2022
Adcentrx Therapeutics Announces Completion of $50M Series A Financing Led By CBC Group To Accelerate Next-Generation Conjugate Drugs Research & DevelopmentApril 28, 2021
